Diagnostic value of video-oculography in progressive supranuclear palsy: a controlled study in 100 patients.

Diagnostic marker Oculomotor function Parkinsonism Progressive supranuclear palsy Video-oculography

Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 18 01 2021
accepted: 12 03 2021
revised: 10 03 2021
pubmed: 22 3 2021
medline: 14 8 2021
entrez: 21 3 2021
Statut: ppublish

Résumé

The eponymous feature of progressive supranuclear palsy (PSP) is oculomotor impairment which is one of the relevant domains in the Movement Disorder Society diagnostic criteria. We aimed to investigate the value of specific video-oculographic parameters for the use as diagnostic markers in PSP. An analysis of video-oculography recordings of 100 PSP patients and 49 age-matched healthy control subjects was performed. Gain of smooth pursuit eye movement and latency, gain, peak eye velocity, asymmetry of downward and upward velocities of saccades as well as rate of saccadic intrusions were analyzed. Vertical saccade velocity and saccadic intrusions allowed for the classification of about 70% and 56% of the patients, respectively. By combining both parameters, almost 80% of the PSP patients were covered, while vertical velocity asymmetry was observed in approximately 34%. All parameters had a specificity of above 95%. The sensitivities were lower with around 50-60% for the velocity and saccadic intrusions and only 27% for vertical asymmetry. In accordance with oculomotor features in the current PSP diagnostic criteria, video-oculographic assessment of vertical saccade velocity and saccadic intrusions resulted in very high specificity. Asymmetry of vertical saccade velocities, in the opposite, did not prove to be useful for diagnostic purposes.

Sections du résumé

BACKGROUND BACKGROUND
The eponymous feature of progressive supranuclear palsy (PSP) is oculomotor impairment which is one of the relevant domains in the Movement Disorder Society diagnostic criteria.
OBJECTIVE OBJECTIVE
We aimed to investigate the value of specific video-oculographic parameters for the use as diagnostic markers in PSP.
METHODS METHODS
An analysis of video-oculography recordings of 100 PSP patients and 49 age-matched healthy control subjects was performed. Gain of smooth pursuit eye movement and latency, gain, peak eye velocity, asymmetry of downward and upward velocities of saccades as well as rate of saccadic intrusions were analyzed.
RESULTS RESULTS
Vertical saccade velocity and saccadic intrusions allowed for the classification of about 70% and 56% of the patients, respectively. By combining both parameters, almost 80% of the PSP patients were covered, while vertical velocity asymmetry was observed in approximately 34%. All parameters had a specificity of above 95%. The sensitivities were lower with around 50-60% for the velocity and saccadic intrusions and only 27% for vertical asymmetry.
CONCLUSIONS CONCLUSIONS
In accordance with oculomotor features in the current PSP diagnostic criteria, video-oculographic assessment of vertical saccade velocity and saccadic intrusions resulted in very high specificity. Asymmetry of vertical saccade velocities, in the opposite, did not prove to be useful for diagnostic purposes.

Identifiants

pubmed: 33744980
doi: 10.1007/s00415-021-10522-9
pii: 10.1007/s00415-021-10522-9
pmc: PMC8357639
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3467-3475

Informations de copyright

© 2021. The Author(s).

Références

Mov Disord. 2017 Jul;32(7):1006-1015
pubmed: 28544256
Vision Res. 2004 Oct;44(23):2675-90
pubmed: 15358063
Arch Neurol. 1964 Apr;10:333-59
pubmed: 14107684
Brain. 1989 Apr;112 ( Pt 2):471-87
pubmed: 2706440
Vision Res. 2010 Apr 7;50(8):761-71
pubmed: 20123108
Mov Disord. 2014 Dec;29(14):1758-66
pubmed: 25370486
Front Neurol. 2010 Dec 03;1:147
pubmed: 21188269
Curr Opin Neurol. 2010 Aug;23(4):394-400
pubmed: 20610990
Neurology. 2000 Mar 14;54(5):1029-32
pubmed: 10720270
J Neurol. 2008 Dec;255(12):1916-25
pubmed: 19224319
Parkinsonism Relat Disord. 2011 May;17(4):223-30
pubmed: 20801069
Clin Neurophysiol. 2013 Feb;124(2):354-63
pubmed: 22883477
Mov Disord. 2019 Aug;34(8):1228-1232
pubmed: 30884545
J Eye Mov Res. 2019 Sep 16;12(6):
pubmed: 33828758
Front Neurol. 2018 May 07;9:319
pubmed: 29867729
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
J Neurol. 2017 Sep;264(9):1919-1928
pubmed: 28762086
Mov Disord. 2017 Jul;32(7):995-1005
pubmed: 28500752
Mov Disord. 2019 Aug;34(8):1144-1153
pubmed: 30726566
Brain. 2005 Jun;128(Pt 6):1247-58
pubmed: 15788542
J Neurol. 2021 Mar;268(3):967-977
pubmed: 32959131
J Ophthalmol. 2014;2014:658243
pubmed: 24955249
Arch Neurol. 2012 Apr;69(4):509-17
pubmed: 22491196
Nat Rev Neurol. 2013 Feb;9(2):74-85
pubmed: 23338283
J Neurosci. 2011 Mar 23;31(12):4379-87
pubmed: 21430139
Neurodegener Dis. 2017;17(4-5):117-126
pubmed: 28268209
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
Brain Imaging Behav. 2016 Mar;10(1):79-91
pubmed: 25749936
PLoS One. 2015 Nov 11;10(11):e0142546
pubmed: 26559944
Neurology. 2001 Dec 11;57(11):2070-7
pubmed: 11739828
Acta Neuropathol. 2020 Aug;140(2):99-119
pubmed: 32383020
J Neurol. 2014 Apr;261(4):791-803
pubmed: 24535136

Auteurs

Jessica Wunderlich (J)

Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.

Anna Behler (A)

Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.

Jens Dreyhaupt (J)

Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.

Albert C Ludolph (AC)

Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.

Elmar H Pinkhardt (EH)

Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.

Jan Kassubek (J)

Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany. jan.kassubek@uni-ulm.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH